These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia. Kotemul K; Kasinrerk W; Takheaw N Explor Target Antitumor Ther; 2024; 5(1):96-107. PubMed ID: 38468825 [TBL] [Abstract][Full Text] [Related]
8. CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity. Husak Z; Dworzak MN Cell Death Dis; 2012 Nov; 3(11):e425. PubMed ID: 23152061 [TBL] [Abstract][Full Text] [Related]
9. CD99 triggering induces methuosis of Ewing sarcoma cells through IGF-1R/RAS/Rac1 signaling. Manara MC; Terracciano M; Mancarella C; Sciandra M; Guerzoni C; Pasello M; Grilli A; Zini N; Picci P; Colombo MP; Morrione A; Scotlandi K Oncotarget; 2016 Nov; 7(48):79925-79942. PubMed ID: 27835596 [TBL] [Abstract][Full Text] [Related]
10. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes? Tavakkoli M; Chung SS; Park CY Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789 [TBL] [Abstract][Full Text] [Related]
11. Transcriptome Analysis Reveals the Induction of Apoptosis-Related Genes by a Monoclonal Antibody against a New Epitope of CD99 on T-Acute Lymphoblastic Leukemia. Takheaw N; Kotemul K; Chaiwut R; Pata S; Laopajon W; Rangnoi K; Yamabhai M; Kasinrerk W Antibodies (Basel); 2024 May; 13(2):. PubMed ID: 38804310 [TBL] [Abstract][Full Text] [Related]
12. Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment. Kadam S; Ali A; Pospiech M; Onyemaechi S; Meng Y; Dhuri K; MacKay JA; Alachkar H Biomed Pharmacother; 2024 Oct; 179():117265. PubMed ID: 39167846 [TBL] [Abstract][Full Text] [Related]
13. Production and characterization of monoclonal antibodies against recombinant extracellular domain of CD99. Thangaretnam KP; Paramasivam OR; Ramanathan P; Gopisetty G; Rajkumar T Hum Antibodies; 2019; 27(1):69-83. PubMed ID: 30282350 [TBL] [Abstract][Full Text] [Related]
14. Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation. Laopajon W; Pata S; Takheaw N; Surinkaew S; Khummuang S; Kasinrerk W Cell Immunol; 2019 Jan; 335():51-58. PubMed ID: 30396687 [TBL] [Abstract][Full Text] [Related]
15. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Kang LC; Dunphy CH Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553 [TBL] [Abstract][Full Text] [Related]
16. Cell Adhesion Molecule CD99 in Cancer Immunotherapy. Yu F; Liu G; Zhang H; Wang X; Wu Z; Xu Q; Wu Y; Chen D Curr Mol Med; 2023; 23(10):1028-1036. PubMed ID: 36214301 [TBL] [Abstract][Full Text] [Related]
17. CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis. Dorfman DM; Kraus M; Perez-Atayde AR; Barnhill RL; Pinkus GS; Granter SR Mod Pathol; 1997 Apr; 10(4):283-8. PubMed ID: 9110288 [TBL] [Abstract][Full Text] [Related]
18. TDT (-), KIT (+), CD34 (+), CD99 (+) precursor T lymphoblastic leukemia/lymphoma. Terada T Int J Clin Exp Pathol; 2012; 5(2):167-70. PubMed ID: 22400079 [TBL] [Abstract][Full Text] [Related]
19. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Soslow RA; Bhargava V; Warnke RA Hum Pathol; 1997 Oct; 28(10):1158-65. PubMed ID: 9343323 [TBL] [Abstract][Full Text] [Related]
20. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Chung SS; Eng WS; Hu W; Khalaj M; Garrett-Bakelman FE; Tavakkoli M; Levine RL; Carroll M; Klimek VM; Melnick AM; Park CY Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123069 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]